- aBaxalta Innovations GmbH, Part of Takeda Companies, Uferstrasse 15, Orth, 2304, Austria
- bDepartment for Analytical Chemistry, University of Vienna, Vienna, 1090, Austria
- cDoctoral School of Chemistry, University of Vienna, Vienna, 1090, Austria
- dDepartment of Applied Life Sciences, Bioengineering, University of Applied Sciences Campus Vienna, Vienna, 1100, Austria
- ↵*Corresponding author; email: diana.szeliova{at}univie.ac.at
ABSTRACT
HEK293 cells are a versatile cell line extensively used in the production of recombinant proteins and viral vectors, notably Adeno-associated virus (AAV) [12]. Despite their high transfection efficiency and adaptability to various culture conditions, challenges remain in achieving sufficient yields of active viral particles. This study presents a comprehensive multi-omics analysis of two HEK293 strains under good manufacturing practice conditions, focusing on the metabolic and cellular responses during AAV production. The investigation included lipidomic, exometabolomic, and transcriptomic profiling across different conditions and time points. Genome-scale metabolic models (GSMMs) were reconstructed for these strains to elucidate metabolic shifts and identify potential bottlenecks in AAV production. Notably, the study revealed significant differences between a High-producing (HP) and a Low-producing (LP) HEK293 strains, highlighting pseudohypoxia in the LP strain. Key findings include the identification of hypoxia-inducible factor 1-alpha (HIF1alpha) as a critical regulator in the LP strain, linking pseudohypoxia to poor AAV productivity. Inhibition of HIF1alpha resulted in immediate cessation of cell growth and a 2-fold increase in viral capsid production, albeit with a decreased number of viral genomes, impacting the full-to-empty particle ratio. This suggests that while HIF1alpha inhibition enhances capsid assembly, it simultaneously hampers nucleotide synthesis via the pentose phosphate pathway (PPP), necessary for genome packaging.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
- Received October 10, 2024.
- Revision received October 10, 2024.
- Accepted October 10, 2024.
- © 2024, Posted by Cold Spring Harbor Laboratory
This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/